Targeted therapies in hepatocellular carcinoma

Area of Science:

• Hepatology and Oncology
• Molecular Targeted Therapy

Background:

• Hepatocellular carcinoma (HCC) onset is linked to non-neoplastic liver diseases like cirrhosis.
• Despite surveillance, HCC is frequently diagnosed at advanced stages, limiting locoregional treatment options.
• Systemic therapies are crucial for advanced HCC, with sorafenib historically being the primary choice.

Purpose of the Study:

• To review current systemic treatment options for advanced hepatocellular carcinoma (HCC).
• To discuss emerging targeted therapies and biological treatments for HCC.
• To highlight the challenges in defining optimal patient populations and integrating new drugs with standard care.

Main Methods:

• Review of clinical surveillance protocols for chronic liver diseases.
• Analysis of systemic therapy efficacy, including sorafenib in phase III trials.
• Investigation of ongoing research into novel targeted drugs and biological treatments for HCC.

Main Results:

• Sorafenib demonstrated survival benefits, but its efficacy in Child-Pugh B patients remains debated.
• Various targeted drugs, including anti-VEGF/EGFR monoclonal antibodies, tyrosine kinase inhibitors, and mTOR inhibitors, are under development.
• These agents aim to target specific biological pathways driving HCC progression.

Conclusions:

• Advanced HCC management relies on systemic therapies due to limitations in locoregional treatment.
• New targeted drugs offer potential for improved outcomes in HCC.
• Optimizing drug integration and identifying precise patient settings are critical challenges for enhancing survival and quality of life.